Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2017

View Archived Issues

Assembly Biosciences selects second CpAM candidate for clinical development

Medicago begins phase III study of quadrivalent influenza vaccine candidate

Glythera obtains license to CDK11 inhibitor program from Cancer Research UK

Ascendis Pharma begins dosing in phase I study of TransCon PTH

Alnylam Pharmaceuticals begins phase II study of cemdisiran in aHUS

Launch of SpringWorks Therapeutics

Novel MABA bronchodilator CHF-6366 evaluated in vitro and in vivo

Hanmi presents data on HM-15136 for CHI treatment

Immune Pharmaceuticals gives update on phase II study of bertilimumab in severe bullous pemphigoid

Bavencio approved in Japan for Merkel cell carcinoma

SCORES study finds benefit to combining anti-PD-L1 antibody with AZD-9150 in head and neck cancer

FDA grants rare pediatric disease and fast track designations to Audentes' AT-132

First patient treated in phase II study of Genelux's GL-ONC1 in ovarian cancer

TNT-009 shows promise for the treatment of transplant rejection

Vichem Chemie Research patents FGFR inhibitors

AC Immune divulges SNCA-targeting compounds for PET imaging

Bio-Pharm Solutions presents carbamate derivatives

IRE1A inhibitors described in Cornell University patent

CTxT Pty divulges PRMT5 inhibitors

FDA issues complete response letter for Intarcia's ITCA-650

HSP90 inhibitor TAS-116 displays activity and manageable toxicity in phase II GIST trial

Synairgen reports new analysis of phase II INEXAS study of SNG-001 in asthma patients

Novartis and UC Berkeley form alliance to unlock undruggable disease targets

MSD receives approval in Japan for Ziplava to avoid recurrent C. difficile infection

MSD announces approval of Atozet Tablets in Japan

Board recommends continuation of phase III study of CardiAMP stem cell therapy for heart failure

NeRRe Therapeutics launches KaNDy Therapeutics

Lexicon Pharmaceuticals starts dosing in phase I study of LX-9211

European Commission approves Dupixent for atopic dermatitis